Wayfair Inc (W) Stock News

Rosen Law Firm is urging investors who purchased Fluence Energy (FLNC) securities between November 24, 2025 and September 16, 2026 to join a class action lawsuit. The lawsuit alleges that Fluence Energy made materially false statements regarding its ability to deliver backlog and meet fiscal 2026 revenue guidance, citing incomplete manufacturing facilities and unresolved production problems that undermined the company's positive business projections.

The article analyzes four nuclear reactor stocks and their potential valuations by 2031. Oklo, NuScale Power, and Nano Nuclear Energy face significant execution risks with current stock prices appearing to price in substantial post-2031 growth. BWX Technologies, a more established supplier with existing revenue, carries less commercialization risk but trades at a premium valuation with limited upside room.

An analysis of five space stocks projects their valuations by 2030 based on an 18% annual growth rate in the space economy. SpaceX is deemed overpriced at 200x forward earnings, while Redwire and Planet Labs offer modest growth potential. Rocket Lab faces headwinds despite Iridium acquisition, and AST SpaceMobile is significantly overvalued relative to its revenue.

ON Semiconductor, despite a 43% gain in 2026, remains a strong value play due to its exposure to electric vehicles, industrial applications, and fast-growing AI data center infrastructure. Management projects 12-14% revenue CAGR and 30% operating income CAGR through 2030, with the pending Synaptics acquisition expected to strengthen its position in the physical AI market.

Rosen Law Firm is encouraging investors who purchased Hims & Hers Health, Inc. securities between August 4, 2025 and July 29, 2026 to join a class action lawsuit. The lawsuit alleges that Hims made materially false and misleading statements regarding data privacy practices, prescription charging procedures, and regulatory compliance, which subjected the company to potential fees and penalties.

Costco's dividend has grown 86% over the past five years, with current quarterly payouts of $1.47 per share. If historical growth rates continue, a $10,000 investment could generate approximately $115 in annual dividend income by 2031 (1.15% yield), plus potential special dividends. The company's strong fundamentals, consistent same-store sales growth, and $20.2 billion cash position support optimistic dividend growth prospects.

The Schwab U.S. Dividend Equity ETF (SCHD) had only three losing years between 2012-2025, with its worst loss being 5.5% in 2018. While this defensive positioning protected it during market downturns like 2022 (down 3% vs S&P 500 down 18%), it significantly underperformed in rising markets. Over 14 years, $10,000 in SCHD grew to ~$49,000 compared to ~$70,500 in the S&P 500, demonstrating the trade-off between downside protection and upside participation.

Symbotic, a warehouse automation robotics company with a $22.5 billion backlog, is gaining traction with major retailers like Walmart, Albertsons, and Target. Despite recent stock underperformance, analysts remain bullish with a consensus price target 45% above current levels. The global warehouse robotics market is projected to grow at 23.1% annually through 2034, reaching $117.3 billion.

TSMC will report Q3 earnings on Oct. 15 with three key metrics to watch: HPC revenue growth (driven by AI chip demand), 3nm node production expansion, and potential guidance raises. The company already disclosed 50% YoY revenue growth, but investors will scrutinize these numbers as any slowdown could trigger a stock pullback and impact the broader semiconductor sector.

Waymo, Alphabet's autonomous vehicle subsidiary, has reached approximately 500,000 fully autonomous rides per week as of spring 2026, halfway toward its goal of 1 million rides weekly by year-end. While the company may fall short of this target, analyst Daniel Sparks argues Alphabet remains the best robotaxi investment option because Waymo represents only 3% of Alphabet's $4.2 trillion market value, with losses easily covered by Google's core profitable businesses. In comparison, Tesla and Uber face different challenges as robotaxi plays.

Micron Technology stock has surged over 1,100% in the past year and a half due to strong AI-driven demand for memory and storage chips. An analyst predicts the stock could reach approximately $2,070 by the end of 2027, roughly doubling from its current $1,035 price, based on expected revenue growth and a normalized price-to-sales ratio. However, risks include potential supply normalization and slowdowns in AI infrastructure spending.

The market currently exhibits conflicting signals with investors experiencing fear (CNN Fear & Greed Index at 38) while valuation metrics like the Buffett Indicator (237%) and Shiller CAPE ratio suggest greed. Buffett's contrarian investing rule advises being fearful of overvalued growth stocks while seeking greedy opportunities in undervalued sectors like energy and healthcare. Success requires balancing both extremes rather than acting on a single indicator.

Grail's stock surged 80% following a positive FDA panel vote on its Galleri multi-cancer early detection test. However, the article warns investors that while FDA approval and insurer adoption are important, the critical risk factor is the price insurers will be willing to pay for the $949 test, which depends on cost-benefit analyses and clinical data.

Individual investors hold approximately two-thirds of all Bitcoin (14 million BTC), while corporations, ETFs, and governments collectively own only about 13% of the supply. As institutional buyers and governments increasingly seek Bitcoin, they will need to purchase from current individual holders at higher prices, potentially creating a buying opportunity for those willing to hold long-term as supply becomes increasingly constrained.

To generate $1,000 monthly in dividend income ($12,000 annually), investors should diversify across five pharmaceutical stocks rather than concentrating in high-yield Pfizer alone. Investing $70,000 each in Pfizer, Johnson & Johnson, AbbVie, Bristol Myers Squibb, and Amgen creates a balanced portfolio that reduces risk from patent expirations and potential dividend cuts while maintaining steady income.

Cerebras Systems expects $880-890 million in core revenue for 2026, comparable to Nvidia's data center business revenue of $830 million in fiscal 2017. However, the similarities end there. Unlike Nvidia, which had a profitable gaming business funding its AI expansion, Cerebras is unprofitable with negative operating margins and relies on just three customers for three-quarters of revenue. The stock trades at 44x expected revenue and is valued at two-thirds of Nvidia's entire 2016 market cap, raising questions about whether it can replicate Nvidia's growth trajectory.

CoreWeave is a rapidly growing AI-focused cloud provider expanding at 112% year-over-year, compared to AWS's 37% growth. However, AWS maintains a massive 20x size advantage with $42.2B in quarterly revenue versus CoreWeave's $2.1B. At current growth rates, it would take CoreWeave nearly seven years to match AWS's revenue. While CoreWeave presents significant upside potential if it achieves profitability comparable to AWS's 39% operating margin, it currently lacks profitability and faces execution risks.

Moderna stock has surged over 500% this year, driven by investor enthusiasm about its personalized cancer vaccine candidate. The stock now trades 61% above Wall Street's average price target. While the stock may face near-term pullback after its rapid gains, the company's strong pipeline and long-term growth potential in mRNA-based therapies suggest it remains a solid long-term biotech investment, though scaling personalized vaccines presents manufacturing challenges.

Canopy Growth and Tilray Brands represent diverging strategies in the cannabis industry. Canopy pursues a lean, brand-focused model with emphasis on U.S. expansion, while Tilray has diversified into craft beverages and wellness products. Both companies reported significant net losses in FY 2026 despite revenue growth, with Tilray showing better financial metrics (higher revenue, lower debt-to-equity ratio, higher gross margin) but greater business complexity. The article suggests Tilray may appeal to diversification-focused investors, while Canopy attracts those betting on pure cannabis growth, though both carry substantial risks.

Firefly Aerospace and Rocket Lab represent competing approaches in the commercial space industry. Firefly delivers hypergrowth (163% revenue increase) but faces significant cash burn ($237.8M negative FCF) and customer concentration risks, with only 2 years of cash runway. Rocket Lab offers more financial stability with $2.3B net cash and 5 years of runway, but trades at a premium valuation (54x P/S vs. Firefly's 12x). For growth-focused investors seeking value, Firefly's lower valuation may appeal despite higher risks.

Credo Technology is experiencing rapid growth in AI data center networking, with revenue expected to triple by fiscal 2028 as hyperscalers increase capital spending. The company specializes in high-performance cables and networking solutions that prevent costly GPU cluster disruptions. However, heavy customer concentration (61% from two customers) and high valuation multiples present significant risks.

Both Redwire and Rocket Lab are unprofitable space infrastructure companies with strong revenue growth but significant cash burn. Redwire specializes in mission-critical components for defense and civil agencies, while Rocket Lab offers end-to-end launch services and satellite manufacturing. Despite Rocket Lab's higher growth rate (55% vs 29% quarterly YoY), Redwire appears more attractive due to its lower valuation (P/S ratio of 6x vs 54x) and longer cash runway (5 years vs 8 years relative to burn rates). Both remain compelling for growth-oriented investors in the emerging space economy.

Winseed concluded its participation at IAA TRANSPORTATION 2026 in Hanover, highlighting the shift of automotive AI from innovation to commercialization. The company's research identified five major trends: AI moving toward practical deployment, importance of real-world deployment evidence, Chinese automotive brands entering global competition, AI visibility as a new brand competition dimension, and the need for integrated AI-era marketing infrastructure. Winseed emphasizes that future automotive leaders must compete on both technological innovation and ensuring that innovation is accurately understood in international markets.

MercadoLibre emerges as the superior investment choice compared to Coupang, driven by significantly higher revenue growth (39.1% vs 14.1%), superior profitability (6.9% net margin vs 0.6%), and a much larger customer base across 18 countries. While Coupang trades at a lower valuation multiple, MercadoLibre's robust cash flow generation and expanding fintech ecosystem provide better long-term value despite operating in volatile emerging markets.

Abbott Laboratories is positioned for significant growth potential, with analyst projections suggesting the stock could reach approximately $210 per share by 2036 based on conservative 8% annual earnings growth. The healthcare company's strong track record includes a 9.7% compound annual earnings-per-share growth rate over the past decade, bolstered by strategic acquisitions. Abbott's status as a Dividend King with 54 consecutive years of dividend increases, combined with a 2.5% dividend yield, makes it an attractive option for income-focused investors seeking defensive holdings with upside potential.

SpaceX stock has declined from its IPO high despite strong growth prospects in Starlink and Starship. However, the company's AI business segment is a major concern, with operating losses widening from $2.46 billion to $3.73 billion in H1 2026, erasing Starlink's $2.84 billion operating profit. At a 49x sales valuation with a $2.2 trillion market cap, the analyst recommends waiting until SpaceX proves its AI investments are not just a money pit before investing.

ExxonMobil CEO Darren Woods initially called Venezuela 'uninvestable,' but the company is now reportedly in talks to invest in Venezuelan oilfields. However, Venezuela's production capacity remains severely constrained at 1.2 million barrels per day versus its historical peak of 3.5 million, meaning any investment there won't materially impact global oil prices in the near term. For ExxonMobil investors, Venezuela represents a potential bonus rather than a core growth driver, with the company's primary growth engines being its operations in Guyana and the Permian Basin.

D-Wave Quantum Inc. (NASDAQ: QBTS) is under investigation for potential federal securities law violations following disappointing Q2 2026 financial results with revenue of $3.08 million, missing analyst expectations of $4.03-$4.08 million. The company's stock fell over 9% on August 6, 2026, and again on August 26, 2026, following the announcement of its CFO's resignation. Kessler Topaz Meltzer & Check, LLP is encouraging affected investors to contact the firm regarding potential legal claims.

Cathie Wood's Ark Invest sold approximately 55,000 shares of SpaceX from its Next Generation Technology ETF, marking the first reduction since SpaceX went public in June. The sale represents only 0.4% of the ETF's position and is likely a routine rebalancing rather than a loss of confidence. SpaceX's Starlink satellite business continues to drive profitability with 66% revenue growth and doubled subscriber count to 12 million, while the rocket-launching business remains unprofitable.

Coinbase CEO Brian Armstrong reaffirmed his $400,000 Bitcoin price target by 2030 during a podcast interview, citing the cryptocurrency's four-year halving cycle. However, the article argues this target is unrealistic, requiring 48.2% annual compounding over four years and a market cap of $8.2 trillion—roughly five times today's value. While Armstrong's long-term logic about fixed supply and adoption is sound, the specific 2030 deadline appears overly optimistic given Bitcoin's shrinking cycle peaks.